SE442480B - Forfarande for framstellning av en glukoshaltig infusionslosning - Google Patents
Forfarande for framstellning av en glukoshaltig infusionslosningInfo
- Publication number
- SE442480B SE442480B SE7714359A SE7714359A SE442480B SE 442480 B SE442480 B SE 442480B SE 7714359 A SE7714359 A SE 7714359A SE 7714359 A SE7714359 A SE 7714359A SE 442480 B SE442480 B SE 442480B
- Authority
- SE
- Sweden
- Prior art keywords
- glucose
- solution
- quinine
- bradykinin
- infusion
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 53
- 239000008103 glucose Substances 0.000 title claims description 53
- 239000003978 infusion fluid Substances 0.000 title claims description 20
- 238000000034 method Methods 0.000 title claims description 6
- 239000000243 solution Substances 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 101800004538 Bradykinin Proteins 0.000 claims description 10
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 10
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 229910052500 inorganic mineral Chemical class 0.000 claims description 2
- 239000011707 mineral Chemical class 0.000 claims description 2
- 150000002990 phenothiazines Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 102100035792 Kininogen-1 Human genes 0.000 claims 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 46
- 241000157855 Cinchona Species 0.000 description 30
- 235000001258 Cinchona calisaya Nutrition 0.000 description 30
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 23
- 229960000948 quinine Drugs 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 102400000967 Bradykinin Human genes 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 125000003410 quininyl group Chemical group 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229950000688 phenothiazine Drugs 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 235000021092 sugar substitutes Nutrition 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 210000000663 muscle cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical group CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940116298 l- malic acid Drugs 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000010444 Acidosis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108010003195 Kallidin Proteins 0.000 description 1
- FYSKZKQBTVLYEQ-FSLKYBNLSA-N Kallidin Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 FYSKZKQBTVLYEQ-FSLKYBNLSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- -1 methionine Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- JFALSRSLKYAFGM-UHFFFAOYSA-N uranium(0) Chemical compound [U] JFALSRSLKYAFGM-UHFFFAOYSA-N 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2657381A DE2657381C2 (de) | 1976-12-17 | 1976-12-17 | Glucosehaltige Infusionslösung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7714359L SE7714359L (sv) | 1978-06-18 |
| SE442480B true SE442480B (sv) | 1986-01-13 |
Family
ID=5995850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7714359A SE442480B (sv) | 1976-12-17 | 1977-12-16 | Forfarande for framstellning av en glukoshaltig infusionslosning |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4152425A (cs) |
| JP (1) | JPS5914006B2 (cs) |
| AT (1) | ATA904977A (cs) |
| AU (1) | AU517454B2 (cs) |
| CA (1) | CA1077845A (cs) |
| CH (1) | CH638400A5 (cs) |
| DE (1) | DE2657381C2 (cs) |
| FR (1) | FR2374043A1 (cs) |
| GB (1) | GB1545743A (cs) |
| IE (1) | IE46281B1 (cs) |
| NL (1) | NL7713961A (cs) |
| SE (1) | SE442480B (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH639247A5 (de) * | 1979-01-23 | 1983-11-15 | Thera Ges Fuer Patente | Aminosaeuren und mineralsalze enthaltende infusionsloesung. |
| US5385940A (en) * | 1992-11-05 | 1995-01-31 | The General Hospital Corporation | Treatment of stroke with nitric-oxide releasing compounds |
| US20020076782A1 (en) * | 1996-07-05 | 2002-06-20 | John P.N. Rosazza | Purified nitric oxide synthase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE352533B (cs) * | 1967-10-20 | 1973-01-08 | Sandoz Ag | |
| DE2357507C3 (de) * | 1973-11-17 | 1980-07-31 | Bayer Ag, 5090 Leverkusen | Mittel zur Fertilitätssteigemng |
| DE2657382A1 (de) * | 1976-12-17 | 1978-06-29 | Thera Ges Fuer Patente | Orales antidiabetikmittel |
-
1976
- 1976-12-17 DE DE2657381A patent/DE2657381C2/de not_active Expired
-
1977
- 1977-11-29 CH CH1456677A patent/CH638400A5/de not_active IP Right Cessation
- 1977-12-14 CA CA293,050A patent/CA1077845A/en not_active Expired
- 1977-12-15 IE IE2553/77A patent/IE46281B1/en not_active IP Right Cessation
- 1977-12-16 FR FR7738032A patent/FR2374043A1/fr active Granted
- 1977-12-16 SE SE7714359A patent/SE442480B/sv not_active IP Right Cessation
- 1977-12-16 GB GB52488/77A patent/GB1545743A/en not_active Expired
- 1977-12-16 JP JP52150690A patent/JPS5914006B2/ja not_active Expired
- 1977-12-16 NL NL7713961A patent/NL7713961A/xx not_active Application Discontinuation
- 1977-12-16 AT AT904977A patent/ATA904977A/de not_active Application Discontinuation
- 1977-12-16 US US05/861,368 patent/US4152425A/en not_active Expired - Lifetime
- 1977-12-19 AU AU31758/77A patent/AU517454B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| SE7714359L (sv) | 1978-06-18 |
| FR2374043A1 (fr) | 1978-07-13 |
| US4152425A (en) | 1979-05-01 |
| IE46281L (en) | 1978-06-17 |
| NL7713961A (nl) | 1978-06-20 |
| CA1077845A (en) | 1980-05-20 |
| AU3175877A (en) | 1979-06-28 |
| JPS5386010A (en) | 1978-07-29 |
| DE2657381C2 (de) | 1982-03-25 |
| IE46281B1 (en) | 1983-04-20 |
| AU517454B2 (en) | 1981-07-30 |
| ATA904977A (de) | 1979-05-15 |
| JPS5914006B2 (ja) | 1984-04-02 |
| FR2374043B1 (cs) | 1982-06-11 |
| GB1545743A (en) | 1979-05-16 |
| CH638400A5 (de) | 1983-09-30 |
| DE2657381A1 (de) | 1978-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU624595B2 (en) | Method for treating and preventing secondary effects of hyperinsulinemia and for treating type 2 diabetes, obesity and hyperlipidemia by application of insulin-like growth factor (IGF I) | |
| US9668994B2 (en) | Methods and compositions for increasing the anaerobic working capacity in tissues | |
| AUSTGEN et al. | The effects of glutamine-enriched total parenteral nutrition on tumor growth and host tissues | |
| Pentecost et al. | Controlled trial of intravenous glucose, potassium, and insulin in acute myocardial infarction | |
| JPH09512552A (ja) | 腎疾患および不全の治療方法ならびに組成物 | |
| JP2014065740A (ja) | 高齢者の骨格筋量減少を防止又は改善するためのアミノ酸含有組成物 | |
| Gore et al. | Relative influence of glucose and insulin on peripheral amino acid metabolism in severely burned patients | |
| US5276018A (en) | Composition comprising amino acids and methods for decreasing muscle breakdown | |
| EP0666739B1 (en) | An intravenous solution that diminishes body protein and water loss | |
| Ballian et al. | Glucose metabolism in burn patients: the role of insulin and other endocrine hormones | |
| Robertshaw et al. | Strategies for managing the diabetic patient | |
| SE442480B (sv) | Forfarande for framstellning av en glukoshaltig infusionslosning | |
| WO2020043708A1 (en) | Lactate-protected hypoglycemia to treat glycolysis dependent pathological conditions, in particular cancer | |
| CA1334575C (en) | Substitution fluid preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and its salts | |
| Valarini et al. | Anabolic effects of insulin and amino acids in promoting nitrogen accretion in postoperative patients | |
| Deitch et al. | Inducible nitric oxide synthase knockout mice are resistant to diet-induced loss of gut barrier function and intestinal injury | |
| Cuthbertson et al. | Nutrition in the post-traumatic period | |
| JPS5923291B2 (ja) | アミノ酸および無機塩を含有する注入液 | |
| EP0076841A1 (en) | Improved solution for parenteral nutrition | |
| Gazzaniga et al. | Endogenous caloric sources and nitrogen balance: regulation in postoperative patients | |
| Desai et al. | Branched-chain amino acid administration in surgical patients: effects on amino acid and fuel substrate profiles | |
| Macbryde et al. | Pork adrenal-cortex extract: effect upon carbohydrate metabolism and work capacity in Addison's disease | |
| Johnston | Metabolic foundations of intravenous nutrition | |
| Kinsell et al. | Accentuation of Human Diabetes by “Pituitary Growth Hormone”. | |
| Bozzetti et al. | Metabolic effects of intraportal nutrition in humans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7714359-2 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7714359-2 Format of ref document f/p: F |